His dad was dying. So Daniel built a world-first artificial heart – with pipes and magnets
Exclusive
Healthcare

His dad was dying. So Daniel built a world-first artificial heart – with pipes and magnets

Australia will spend $50 million building the world’s first long-term artificial heart,after the original prototype was built with pieces bought from Bunnings.

  • bySherryn Groch

Latest

Failed drug trial overshadows CSL’s bumper profits

Failed drug trial overshadows CSL’s bumper profits

Investors have punished the company’s share price for the second day in a row – despite it booking revenue of $12.3 billion for the half-year to December 31.

  • byDavid Swan
Health behemoth CSL sheds $7b in value after heart drug fails trial

Health behemoth CSL sheds $7b in value after heart drug fails trial

Shares in the blood plasma treatments maker were trading nearly 5 per cent lower following the results.

  • byMillie Muroi
Australia underspends on this key area. It may put national security at risk
Exclusive
Education

Australia underspends on this key area. It may put national security at risk

Australia’s underinvestment in research is becoming a national security issue,some university heads argue,ahead of a landmark review and the AUKUS deal.

  • bySherryn Groch andDaniella White
Growing frustration for seaweed farmer at Labor’s ‘incredibly slow’ action to cut cow methane

Growing frustration for seaweed farmer at Labor’s ‘incredibly slow’ action to cut cow methane

After rubbing shoulders in Singapore with Prince William,Sea Forest founder Sam Elsom is eager for the Albanese government to back his plan to help save the planet.

  • byChris Barrett
Prince William rallies against climate denialism at Earthshot Prize

Prince William rallies against climate denialism at Earthshot Prize

The winners of the environmental awards,established by the heir to the British throne,each received $1.91 million in prize money after being announced in Singapore.

  • byChris Barrett
Advertisement
Shedding fat without losing muscle is next weight-loss target for pharma giant

Shedding fat without losing muscle is next weight-loss target for pharma giant

Muscle-mass preservation is becoming a hot new area in obesity medicine.

  • byMadison Muller andCynthia Koons
It’s throwing its weight around,but can Ozempic reshape our economy?

It’s throwing its weight around,but can Ozempic reshape our economy?

From health to fast food,investors are starting to question which companies will be slimmed thanks to weight-loss drugs.

  • byEmma Koehn andColin Kruger
Our biggest healthcare company says it isn’t scared of Ozempic

Our biggest healthcare company says it isn’t scared of Ozempic

CSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.

  • byEmma Koehn
‘Every reason to be grumpy’:CSL defends share price to investors

‘Every reason to be grumpy’:CSL defends share price to investors

Shareholders have grilled the biotech giant about its long-term strategy as the stock sits close to 10 per cent lower for the year.

  • byEmma Koehn
CSL aims to get better bang for buck from plasma

CSL aims to get better bang for buck from plasma

The ASX heavyweight and the nation’s largest healthcare company is looking to make its operations more efficient to counter inflation and currency woes.

  • byEmma Koehn